TROV Stock Chart

Trovagene is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies.